Search research articles
Contact Us
Filters
Showing results (111-120 of 163) with videos related to
Page
of 17
Sort By:
Alimentary Pharmacology & Therapeutics
|
April 24, 2012
Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study
F Zorzi, S Zuzzi, S Onali, et al.
Gut
|
November 1, 1995
Transglutaminases in Crohn's disease
G D'Argenio, L Biancone, V Cosenza, et al.
Diseases of the Colon and Rectum
|
April 1, 1985
Melanosis of the rectum in patients with chronic constipation
D Badiali, A Marcheggiano, F Pallone, et al.
Alimentary Pharmacology & Therapeutics
|
January 15, 2016
Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease
G Monteleone, A Di Sabatino, S Ardizzone, et al.
Journal of Clinical Microbiology
|
December 17, 1997
Salivary immunoglobulin G assay to diagnose Helicobacter pylori infection in children
F Luzza, G Oderda, M Maletta, et al.
Journal of Clinical & Laboratory Immunology
|
April 1, 1986
Raised serum levels of IgM-rheumatoid factor and anti-F(ab')2 autoantibodies in patients with active inflammatory bowel disease
F Pallone, P M Matricardi, O Squarcia, et al.
Gastroenterologie Clinique Et Biologique
|
January 1, 1991
Phenotypes and spontaneous immunoglobulin production in mononuclear cells suspensions isolated from colonic biopsies of patients with mild active and quiescent ulcerative colitis
O Squarcia, S Fais, M Boirivant, et al.
Gastroenterology
|
May 30, 1998
Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis
X Geng, L Biancone, H H Dai, et al.
FEMS Immunology and Medical Microbiology
|
June 23, 1999
Changes in the mucosal expression of interleukin 15 in Helicobacter pylori-associated gastritis
F Luzza, T Parrello, G Monteleone, et al.
Regulatory Peptides
|
March 5, 1992
Modulation of human natural killer activity by vasoactive intestinal peptide (VIP) family. VIP, glucagon and GHRF specifically inhibit NK activity
M C Sirianni, B Annibale, F Tagliaferri, et al.
Page
of 17
Search research articles
Search
Showing results (111-120 of 163) with videos related to
Sort By:
Page
of 17
Alimentary Pharmacology & Therapeutics
|
April 24, 2012
Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study
F Zorzi, S Zuzzi, S Onali, et al.
Gut
|
November 1, 1995
Transglutaminases in Crohn's disease
G D'Argenio, L Biancone, V Cosenza, et al.
Diseases of the Colon and Rectum
|
April 1, 1985
Melanosis of the rectum in patients with chronic constipation
D Badiali, A Marcheggiano, F Pallone, et al.
Alimentary Pharmacology & Therapeutics
|
January 15, 2016
Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease
G Monteleone, A Di Sabatino, S Ardizzone, et al.
Journal of Clinical Microbiology
|
December 17, 1997
Salivary immunoglobulin G assay to diagnose Helicobacter pylori infection in children
F Luzza, G Oderda, M Maletta, et al.
Journal of Clinical & Laboratory Immunology
|
April 1, 1986
Raised serum levels of IgM-rheumatoid factor and anti-F(ab')2 autoantibodies in patients with active inflammatory bowel disease
F Pallone, P M Matricardi, O Squarcia, et al.
Gastroenterologie Clinique Et Biologique
|
January 1, 1991
Phenotypes and spontaneous immunoglobulin production in mononuclear cells suspensions isolated from colonic biopsies of patients with mild active and quiescent ulcerative colitis
O Squarcia, S Fais, M Boirivant, et al.
Gastroenterology
|
May 30, 1998
Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis
X Geng, L Biancone, H H Dai, et al.
FEMS Immunology and Medical Microbiology
|
June 23, 1999
Changes in the mucosal expression of interleukin 15 in Helicobacter pylori-associated gastritis
F Luzza, T Parrello, G Monteleone, et al.
Regulatory Peptides
|
March 5, 1992
Modulation of human natural killer activity by vasoactive intestinal peptide (VIP) family. VIP, glucagon and GHRF specifically inhibit NK activity
M C Sirianni, B Annibale, F Tagliaferri, et al.
Page
of 17